Tirzepatide
LY3298176
Tirzepatide is a synthetic peptide studied in in-vitro and preclinical research as a dual agonist of the GLP-1 and GIP receptors. Research reagent only — not for human consumption or medical use.

Key facts
- Class
- Dual incretin agonist
- Targets
- GLP-1 / GIP
- Form
- Lyophilised (powder)
- Status
- Research Use Only
Study library
All results on PubMedEfficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Kadowaki T, et al. · The lancet. Diabetes & endocrinology · 2025
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
Rodriguez PJ, et al. · JAMA internal medicine · 2024
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, et al. · The New England journal of medicine · 2025
Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.
Khawaji A, et al. · Journal of obesity · 2025
Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).
Wilson L, et al. · Diabetes, obesity & metabolism · 2026
Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.
Snaith JR, et al. · Diabetes care · 2026
Tirzepatide: Clinical review of the "twincretin" injectable.
Krauss Z, et al. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Heise T, et al. · Diabetes care · 2023
Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).
Ng CD, et al. · Advances in therapy · 2025
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
Packer M, et al. · Journal of the American College of Cardiology · 2025
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
Ravussin E, et al. · Cell metabolism · 2025
Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
Shukla AP, et al. · Diabetes, obesity & metabolism · 2026
Results retrieved live from PubMed (NCBI). Research literature only — no medical advice.
Research peptides — Research Use Only
- Not for human consumption
- Not for the diagnosis, treatment or prevention of any disease
